# Abilita Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abilita-bio

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.abilitabio.com
- Total disclosed funding: $7.5M
- Latest round: Seed (Dec 9, 2022)
- Investors on record: 1

## About

Based in California, US, and founded by Mauro Mileni (CEO) in 2014, Abilita Bio, Inc. operates as a biotechnology company specializing in the discovery and development of small molecule therapeutics. In February 2023, the firm raised USD 7.5 million in venture funding led by investor Two Bear Capital.

The company focuses on the discovery and development of drugs targeting specific disease-associated membrane proteins including G Protein-Coupled Receptors (GPCRs) and ion channels to develop therapies for various diseases including cancer, fibrosis, and immunological disorders. The company’s lead program is focused on developing a small molecule inhibitor for the treatment of triple-negative breast cancer through EMP™ (enabled membrane proteins) technology. The other list of target therapies in the pipeline by Abilita is GPCR1 targeting immune-oncology and GPCR2 oncology in optimization state as of March 2023, and Ion Channel 1 and 2 for pain in the discovery stage.

The company plans to utilize the February 2023 funding to expand its business operation in San Diego.

## Funding rounds

- Seed, Dec 9, 2022, $7.5M — Two Bear Capital

## Investors

- Two Bear Capital (https://capitalatlas.ai/funds/two-bear-capital) — Seed